CRVS vs ORIC
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CRVS · Corvus Pharmaceuticals$10.54 ▲ 8.32%
ORIC · Oric Pharmaceuticals$8.82 ▲ 3.89%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CRVS +33.2%
- ORIC -29.2%
Head to head
| Metric | CRVS | ORIC |
|---|---|---|
| Price | $10.54 | $8.82 |
| Change today | ▲ 8.32% | ▲ 3.89% |
| Market cap | $889.08M | $914.22M |
| Return, 3 months | -23.3% | -35.2% |
| Return, year to date | +36.9% | +7.8% |
| Return, 1 year | +38.7% | -28.6% |
| P/E (TTM) | – | – |
| P/B | 4.3 | 2.4 |
| P/E percentile vs own 5y | 18th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -124.5% | -14.1% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -35.4% | -39.8% |
| Analyst target vs. price | +172.8% | +167.1% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 50 | 35 |
| 30-day volatility | 61.8% | 129.0% |
| Max drawdown, 1 year | -63.2% | -46.1% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ORIC is the largest of the group by market value.
- CRVS has returned the most over the past year.
- CRVS has been the calmest stock over the last 30 days.